Empower Your Fight Against Liver Cancer
Liver cancer presents profound treatment challenges. Discover how banking your living tumor tissue can help decipher its complex microenvironment and unlock targeted systemic options.
Talk to a Care SpecialistWhat is Liver Cancer?
Liver cancer, most commonly Hepatocellular Carcinoma (HCC), begins in the main type of liver cells. It often develops in the setting of chronic liver disease or cirrhosis.
Because the liver is a central filtering organ with a unique blood supply, these tumors are notoriously resistant to many conventional chemotherapies.
What Does Liver Cancer Do?
The tumor disrupts the liver's essential metabolic and filtering functions.
- Metabolic Interference: Impairs the body's ability to process nutrients and clear toxins, leading to severe fatigue and jaundice.
- Vascular Complications: Tumors can invade the portal vein, deeply complicating surgical removal.
- Systemic Decline: Decreased liver function can cause fluid accumulation in the abdomen (ascites) and internal bleeding.
Current Treatment Options
Surgical Resection or Transplant
Removing the tumor or replacing the entire liver is the most curative option for early-stage disease.
Ablation or Embolization
Methods to destroy the tumor without removing it, or blocking its blood supply directly through the hepatic artery.
Targeted Therapy & Immunotherapy
For advanced stages, kinase inhibitors or immune checkpoint inhibitors represent the primary systemic approach.
Why Bank Your Living Liver Tissue?
Liver tumors aggressively develop resistance mechanisms. Retaining the living tissue allows researchers to isolate and test specific targeted agents against your highly individual cellular architecture.
Kinase Inhibitor Profiling
Assess how specific targeted therapies bind and react to your unique tumor cells ex-vivo.
Immunotherapy Modeling
Culturing liver tumor cells allows for immune-evasion mapping to see which biologics actually work.
Clinical Trial Readiness
Maintain biological eligibility for novel metabolic trials demanding fresh tissue models.
Future-Proofing
Should initial systemic therapies fail, having the baseline tissue alive provides a blueprint for secondary interventions.